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IgG4-related disease (IgG4-RD) is a fibro-inflammatory 
condition characterized mainly by tissue infiltration by 
IgG4+ plasma cells with a tendency to mass forming. 
IgG4-RD can involve any part of the body, including the 
skin. We report here a rare case of cutaneous IgG4-RD pre-
senting with a nasal infiltrative lesion. To our knowledge, 
this is the first report of this rare clinical presentation.
CASE REPORT
A 67-year-old man with no relevant clinical history presented with 
an erythematous asymptomatic plaque in the nasal ala, which had 
appeared 6 months earlier. The lesion spread progressively to the 
entire nasal pyramid and left infraorbital region (Fig. 1a). He had 
no systemic symptoms. Blood count, biochemical profile and 
haemostasis were normal, and bacterial, fungal and mycobacterial 
cultures were unremarkable. Computed tomography (CT) scan 
and magnetic resonance imaging (MRI) showed a large infiltrative 
lesion affecting cutaneous and subcutaneous tissue in both nasal 
alae (Fig. S1a1). Positron emission tomography (PET) scanning 
confirmed the findings (Fig. S1b1). Thoraco-abdominal CT scan 
was performed and no relevant anomalies were detected. Serum 
protein analysis showed increased levels of gamma-globulins with 
total IgG levels of 19.2 g/l (normal 7.5–16 g/l) and IgG4 3.8 g/l 
(0.08–1.4 g/l). Serological tests for human immunodeficiency virus 
(HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and anti-
neutrophil cytoplasmic antibodies (ANCA) were negative. Biopsy 
of the lesion revealed a dense dermic lymphoplasmacytic infiltrate 
with a background of neutrophils, eosinophils and histiocytes with 
prominent storiform fibrotic stroma (Fig. 2a). Focal images of 
lymphocytic venulitis without necrosis were also observed (Fig. 
2b). Immunohistochemical analysis highlighted 
a large number of IgG4+ plasma cells (Fig. 2c). 
IgG4+ plasma cells were present at approximately 
60–140 per high-power field (Fig. 2d). The ratio of 
IgG4+/IgG plasma cells ranged from 30% to 70%. 
Epstein-Barr virus hybridization was negative and 
clonal rearrangements in the T-cell receptor were 
not detected. Based on these findings a diagnosis 
of IgG4-RD was finally established. Methyl-
prednisolone, 0.5 mg/kg/8 h iv, was initiated for 
1 week. Subsequently, prednisone was changed 
to 0.5 mg/kg day for 2 weeks with progressive 
decrease until a maintenance dose of 5 mg/day. 
After one month, the lesion had disappeared 
(Fig. 1b) and serum IgG4 levels decreased until 
normalization. After 8 months, the corticosteroids 
were stopped, and there is no evidence of disease recurrence after 
3 years of follow-up.
DISCUSSION
IgG4-RD is a recently described clinical entity characte-
rized by tissue infiltration of IgG4+ plasma cells, variable 
degree of fibrosis and often, but not always, elevated 
serum concentrations of IgG4, which was recognized as 
a systemic condition in 2003 (1). Since then, many medi-
cal conditions, such as Mikulicz’s syndrome, Kuttner’s 
tumour, and Riedel’s thyroiditis, which were previously 
known as organ-specific disorders, have been classed as 
part of the spectrum of IgG4-RD (2).
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Fig. 1. Clinical findings. (a) Large inflammatory tumour involving the 
nose, left cheek and infraorbital region. (b) Four weeks after the start of 
steroid therapy. Marked signs of scarring and atrophy are visible.
Fig. 2. Histological and immunohistological findings. (a) 
A skin biopsy specimen showed lymphoplasmacytic infiltrate 
with storiform fibrosis (H&E 40×). (b) Lymphocytes, plasma 
cell, eosinophils and focus of lymphocytic venulitis (H&E, 
40×). (c) Immunohistochemical staining of IgG4 showed 
dense infiltration of IgG4+ plasma cells. (d) High-power 
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The pathogenesis of IgG4-RD is poorly understood; 
findings consistent with both an autoimmune disorder 
and an allergic disorder may be present (3, 4). Affected 
patients are primarily middle-aged and older men (5), 
although rare paediatric cases have been described (6).
The disease can manifest in almost any organ or ana-
tomical site; the most common are the pancreas, biliary 
tract, and salivary and lacrimal glands. However, cutaneous 
involvement is rare (7). IgG4-RD typically manifests in 
the skin as papules or plaques, which can be solitary or 
grouped, and are sometimes described as mass or subcu-
taneous nodules. A rare case of alopecia has been reported 
(8). The most commonly affected regions are the head, 
face and neck; however, lesions have also been seen on 
the trunk and limbs. In addition, IgG4-related skin disease 
usually accompanies extracutaneous symptoms (79%). 
Cases affecting only the skin, as described here, are extre-
mely rare. A review of case reports has postulated 7 dif-
ferent cutaneous presentations of IgG4-RD: (i) cutaneous 
plasmacytosis, (ii) pseudolymphoma and angiolymphoid 
hyperplasia with eosinophilia, (iii) Mikulicz’s disease, (iv) 
psoriasis-like eruption, (v) unspecified maculopapular or 
erythematous eruptions, (vi) hypergammaglobulinaemic 
purpura and urticarial vasculitis, and (vii) ischaemic digit. 
It is considered that subtypes 1–3 are primary IgG4-related 
skin diseases, induced by direct infiltration of IgG4+ plasma 
cells. Meanwhile, secondary IgG4-related skin disease 
shows inflammatory skin manifestations of systemic IgG4-
RD (9). Although the diagnosis of IgG4-RD is based on 
the combination of clinical features, serology, imaging, 
histopathology and immunohistochemistry findings, histo-
pathology is the key component for diagnosing IgG4-RD. 
An international consensus statement on the pathology of 
IgG4-RD was published in 2012, according to which the di-
agnosis should be based primarily on general morphological 
criteria in routine staining. The main microscopic findings 
in tissue include a lymphoplasmacytic infiltrate, storiform 
fibrosis and obliterative phlebitis (10). Tissue IgG4 counts 
and IgG4+/IgG ratios are of secondary importance. An 
IgG4+/IgG ratio greater than 40% is considered supportive 
of IgG4-RD. The exact cut-off for IgG4 count differs in dif-
ferent organs and, for skin, it set at 200 per high-power field. 
However, this value is based on a limited number of cases 
and is not widely accepted. Since many reports do not meet 
this diagnostic criteria it has been suggested that the cut-off 
value should be reconsidered (11). Elevated concentration 
of serum IgG4 (>135 mg/dl) is another characteristic of the 
disease, although serum IgG4 concentration may be normal 
in 30–40% of patients with histopathologically confirmed 
IgG4-RD (12). Imaging studies reveal an increase in the size 
of the affected organ or a regional fibrosing compromise. 
PET scan allows detection of increased metabolism in the 
affected organs, but does not differentiate between the other 
aetiologies with this pattern. 
Differential diagnosis of IgG4-RD is broad and depends 
on the specific site of involvement and clinical presenta-
tion. In our case, the differential diagnosis was based 
mainly on the extranodal natural killer (NK)/T-cell lym-
phoma, nasal type and granulomatosis with polyangiitis. 
There are no treatment guidelines for exclusive skin 
IgG4, and most of the data come from patients with syste-
mic involvement. Systemics glucocorticoids are currently 
the first-line treatment for IgG4-RD (13), regardless of 
the organ involved. Response to glucocorticoid therapy is 
usually seen within days or weeks, often accompanied by 
a decrease in serum IgG4 levels. Skin lesions of IgG4-RD 
respond well to oral glucocorticoids, but the response to 
topical corticosteroids is poor. In refractory cases, surgery, 
immunosuppressive agents, thalidomide, infliximab and 
rituximab, according to involvement (single-organ or 
systemic) and the severity of the disease can be consi-
dered (14, 15). 
In conclusion, the cutaneous manifestations of IgG-RD 
are poorly understood. This new case with an unusual pre-
sentation will enable better characterization of the disease.
REFERENCES
1. Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, 
et al. A new clinicopathological entity of IgG4-related autoim-
mune disease. J Gastroenterol 2003; 38: 982–984.
2. Charrow A, Imadojemu S, Stephen S, Ogunleye T, Takeshita 
J, Lipoff JB. Cutaneous manifestations of IgG4-related disease 
(RD): a systematic review. J Am Acad Dermatol 2016; 75: 
197–202.
3. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki 
T, et al. A novel clinical entity, IgG4-related disease (IgG4RD): 
general concept and details. Mod Rheumatol 2012; 22: 1–14.
4. Stone JS, Yoh Z, Vikram D. IgG4-related disease. N Engl J Med 
2012; 366: 539–551. 
5. Kempeneers D, Hauben E, De Haes P. IgG4-related skin lesions: 
case report and review of the literature. Clin Exp Dermatol 
2014; 39: 479–483.
6. Griepentrog GJ, Vickers RW, Karesh JW, Azari AA, Albert DM, 
Bukat CN. A clinicopathologic case study of two patients with 
pediatric orbital IgG4-related disease. Orbit 2013; 32: 389–391.
7. Ise M, Yasuda F, Suzaki R, Kurihara S, Konohana I. Skin lesions 
in a patient with IgG4-related disease. Clin Exp Dermatol 
2014; 39: 713–716.
8. Ikeda T, Kaminaka C, Furukawa F. A case of alopecia as IgG4-
related skin disease. Mod Rheumatol 2016; 23: 1–4. 
9. Tokura Y, Yagi H, Yanaguchi H, Majima Y, Kasuya A, Ito T, et al. 
IgG4-related skin disease. Br J Dermatol 2014; 171: 959–967.
10. Deshpande V, Zen Y, Chan JK, Yi EE, Sato Y, Yoshino T, et 
al. Consensus statement on the pathology of IgG4-related 
disease. Mod Pathol 2012; 25: 1181–1192. 
11. Sato Y, Takeuchi M, Takata K, Ohno K, Iwaki N, Orita Y, et al. 
Clinicopathologic analysis of IgG4-related skin disease. Mod 
Pathol 2013; 26: 523–532.
12. Sah RP, Chari ST. Serologic issues in IgG4-related systemic 
disease and autoimmune pancreatitis. Curr Opin Rheumatol 
2011; 23: 108–113. 
13. Khosroshahi A, Wallace ZS, Crowe JL, Akamizu T, Azumi A, Car-
ruthers MN, et al. Second International Symposium on IgG4-
Related Disease International consensus guidance statement 
on the management and treatment of IgG4-related disease. 
Arthritis Rheumatol 2015; 67: 1688–1699. 
14. Ingen-Housz-Oro S, Ortonne N, Elhai M, Allanore Y, Aucou-
turier P, Chosidow O. IgG4-related skin disease successfully 
treated by thalidomide: a report of 2 cases with emphasis on 
pathological aspects. JAMA Dermatol 2013; 149: 742–747.
15. Jalilian C, Prince HM, McCormack C, Lade S, Cheah CY. IgG4-
related disease with cutaneous manifestations treated with 
rituximab: case report and literature review. Australas J Der-
matol 2014; 55: 132–136.
